In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Buys into New Pharma World Order

Executive Summary

In paying $5.1 billion for vaccine maker Chiron, Novartis is pursuing a unique business strategy which recognizes the growing role of governments, both as purchasers and as price-setters. The same strategy assumes, too, that pharma must seek alternative growth sources to branded prescription drugs.

You may also be interested in...



Novartis Plans to Move Infectious Disease Research Group to the Bay Area

The company has hired a high-profile professor with a nose for virus sleuthing as its new ID chief, and it will start shifting its 120-member R&D staff from the Boston area next year.

Price Isn't Enough: Sandoz Hones Biosimilars Strategy With Lessons From Omnitrope

As FDA fleshes out the beginnings of a biosimilar regulatory pathway in the U.S., Novartis AG's generics business Sandoz is starting to draw important lessons in how to effectively commercialize copy-cat biologics.

Novartis Gets Bricks And Mortar Money: Last Vaccine Support From Bush Administration

Commercial production at North Carolina facility supported by the HHS grant is at least three years away.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel